Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -
- Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies –
-Two Phase 2a studies currently enrolling patients with hyperuricemia and CKD -
- Initial bioactivity data expected in late 2021 or early 2022 -
https://finance.yahoo.com/news/allena-pharmaceuticals-receives-fast-track-120000047.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.